545 related articles for article (PubMed ID: 29271260)
1. Protein biomarkers for subtyping breast cancer and implications for future research.
Mueller C; Haymond A; Davis JB; Williams A; Espina V
Expert Rev Proteomics; 2018 Feb; 15(2):131-152. PubMed ID: 29271260
[TBL] [Abstract][Full Text] [Related]
2. High-throughput proteomics of breast cancer subtypes: Biological characterization and multiple candidate biomarker panels to patients' stratification.
Azevedo ALK; Gomig THB; Batista M; Marchini FK; Spautz CC; Rabinovich I; Sebastião APM; Oliveira JC; Gradia DF; Cavalli IJ; Ribeiro EMSF
J Proteomics; 2023 Aug; 285():104955. PubMed ID: 37390896
[TBL] [Abstract][Full Text] [Related]
3. Integrating proteomic and phosphoproteomic data for pathway analysis in breast cancer.
Ren J; Wang B; Li J
BMC Syst Biol; 2018 Dec; 12(Suppl 8):130. PubMed ID: 30577793
[TBL] [Abstract][Full Text] [Related]
4. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
5. Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes.
Gajbhiye A; Dabhi R; Taunk K; Jagadeeshaprasad MG; RoyChoudhury S; Mane A; Bayatigeri S; Chaudhury K; Santra MK; Rapole S
J Proteomics; 2017 Jun; 163():1-13. PubMed ID: 28495502
[TBL] [Abstract][Full Text] [Related]
6. Subtyping of breast cancer using reverse phase protein arrays.
Sonntag J; Schlüter K; Bernhardt S; Korf U
Expert Rev Proteomics; 2014 Dec; 11(6):757-70. PubMed ID: 25400094
[TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
[TBL] [Abstract][Full Text] [Related]
8. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
9. Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer.
Zhang L; Xiao H; Karlan S; Zhou H; Gross J; Elashoff D; Akin D; Yan X; Chia D; Karlan B; Wong DT
PLoS One; 2010 Dec; 5(12):e15573. PubMed ID: 21217834
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer classification by proteomic technologies: current state of knowledge.
Lam SW; Jimenez CR; Boven E
Cancer Treat Rev; 2014 Feb; 40(1):129-38. PubMed ID: 23891266
[TBL] [Abstract][Full Text] [Related]
11. Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping.
Rontogianni S; Synadaki E; Li B; Liefaard MC; Lips EH; Wesseling J; Wu W; Altelaar M
Commun Biol; 2019; 2():325. PubMed ID: 31508500
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
Tang P; Tse GM
Arch Pathol Lab Med; 2016 Aug; 140(8):806-14. PubMed ID: 27472239
[TBL] [Abstract][Full Text] [Related]
13. Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer.
Suman S; Basak T; Gupta P; Mishra S; Kumar V; Sengupta S; Shukla Y
J Proteomics; 2016 Oct; 148():183-93. PubMed ID: 27498393
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
[TBL] [Abstract][Full Text] [Related]
15. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.
Clark SE; Warwick J; Carpenter R; Bowen RL; Duffy SW; Jones JL
Br J Cancer; 2011 Jan; 104(1):120-7. PubMed ID: 21139586
[TBL] [Abstract][Full Text] [Related]
17. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid.
Whelan SA; He J; Lu M; Souda P; Saxton RE; Faull KF; Whitelegge JP; Chang HR
J Proteome Res; 2012 Oct; 11(10):5034-45. PubMed ID: 22934887
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging.
Gonçalves JPL; Bollwein C; Noske A; Jacob A; Jank P; Loibl S; Nekljudova V; Fasching PA; Karn T; Marmé F; Müller V; Schem C; Sinn BV; Stickeler E; van Mackelenbergh M; Schmitt WD; Denkert C; Weichert W; Schwamborn K
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769215
[TBL] [Abstract][Full Text] [Related]
20. Clinical proteomics and breast cancer.
Zeidan BA; Townsend PA; Garbis SD; Copson E; Cutress RI
Surgeon; 2015 Oct; 13(5):271-8. PubMed ID: 25736469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]